comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Risk of major adverse events stroke associated treatment with or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis GLP1 Receptor Agonists vs SGLT2-I

In some of the large-scale clinical studies evaluating the safety of GLP-1RAs against CV disease, the effect on kidneys was evaluated as a secondary endpoint

How may GIP Enhance the therapeutic efficacy of GLP-1

Moreover, efpeglenatide therapy reduced the risk of CV disease by about 27% compared to the placebo in the Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O) study [51]

Volume values characterize the mean volume of the circular area centered around the foveola, corresponding to the 6 mm ring of the circular grid defined by the Early Treatment Diabetic Retinopathy Study [23]

However, immune neutralization of GIP or removal of GIP from intestinal extracts does not completely eliminate the insulin-stimulating activity, indicating that there are other substances with insulin-stimulating activity in the intestine (Drucker, 1998)